Initial clinical trial of dibromodulcitol (NSC-104800) in patients with advanced cancer.
D000328:Adult; D000368:Aged; D000477:Alkylating Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D001792:Blood Platelets; D001853:Bone Marrow / Q000187:drug effects; D001966:Bromine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004285:Dogs; D004361:Drug Tolerance; D005069:Evaluation Studies as Topic; D004376:Galactitol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000882:Haplorhini; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007939:Leukemia L1210 / Q000188:drug therapy; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D013402:Sugar Alcohols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced
D000477:Alkylating Agents; D013402:Sugar Alcohols; D004376:Galactitol; D001966:Bromine